Metabolic abnormalities in lymphoma.
Metabolic abnormalities occur relatively frequently in lymphoma patients undergoing chemotherapy. These abnormalities include hyperuricemia, hypercalcemia, hyperphosphatemia, hypocalcemia, hypomagnesemia, hyponatremia, and hyperkalemia. In addition, tumor lysis syndrome can result in several metabolic abnormalities, leading to potential renal failure. If these syndromes are identified promptly, they can be corrected. Guidelines for identifying metabolic abnormalities in lymphoma patients, as well as management suggestions, are presented
Cabanillas
Fernando
F
Centro de Cancer Auxilio Mutuo, San Juan, Puerto Rico. cabanillas@auxilio.com
D000328:Adult; D000493:Allopurinol / Q000627:therapeutic use; D018943:Anthracyclines / Q000627:therapeutic use; D002455:Cell Division; D003404:Creatinine / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D006996:Hypocalcemia / Q000378:metabolism; D017674:Hypophosphatemia / Q000378:metabolism; D008223:Lymphoma / Q000378:metabolism*; D008297:Male; D051437:Renal Insufficiency / Q000378:metabolism; D013997:Time Factors; D015275:Tumor Lysis Syndrome / Q000378:metabolism; D014503:Urate Oxidase / Q000378:metabolism* / Q000627:therapeutic use; D014527:Uric Acid / Q000378:metabolism
D018943:Anthracyclines; D004791:Enzyme Inhibitors; D014527:Uric Acid; D000493:Allopurinol; D003404:Creatinine; D014503:Urate Oxidase